WCM Investment Management LLC Increases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

WCM Investment Management LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 125.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 135,754 shares of the company’s stock after buying an additional 75,584 shares during the period. WCM Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $3,030,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Diversify Advisory Services LLC boosted its holdings in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after buying an additional 496 shares during the period. Sanctuary Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares during the period. Sequoia Financial Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares in the last quarter. DGS Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares during the period. Finally, Smithfield Trust Co lifted its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.84 on Monday. The business’s 50-day moving average price is $20.05 and its 200-day moving average price is $18.51. The firm has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 12 month low of $11.83 and a 12 month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Finally, UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.